statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
AS - Asia	2.554
NA - Nord America	2.195
EU - Europa	983
SA - Sud America	450
AF - Africa	42
OC - Oceania	2
Totale	6.226

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	2.088
SG - Singapore	1.511
HK - Hong Kong	541
BR - Brasile	397
CN - Cina	284
GB - Regno Unito	241
IT - Italia	239
RU - Federazione Russa	231
DE - Germania	82
VN - Vietnam	55
MX - Messico	54
CA - Canada	42
IN - India	33
ZA - Sudafrica	26
FI - Finlandia	24
SE - Svezia	24
TR - Turchia	23
AT - Austria	22
JP - Giappone	21
AR - Argentina	20
BD - Bangladesh	20
PL - Polonia	20
IQ - Iraq	17
NL - Olanda	17
ES - Italia	16
IE - Irlanda	13
LT - Lituania	13
FR - Francia	12
CO - Colombia	9
SA - Arabia Saudita	8
UA - Ucraina	8
UZ - Uzbekistan	8
CH - Svizzera	7
EC - Ecuador	7
CL - Cile	6
KE - Kenya	6
PK - Pakistan	6
AE - Emirati Arabi Uniti	5
EE - Estonia	5
VE - Venezuela	5
NP - Nepal	4
BE - Belgio	3
HN - Honduras	3
IR - Iran	3
AU - Australia	2
BO - Bolivia	2
CZ - Repubblica Ceca	2
ID - Indonesia	2
IL - Israele	2
JO - Giordania	2
KG - Kirghizistan	2
LB - Libano	2
MA - Marocco	2
NI - Nicaragua	2
PE - Perù	2
TN - Tunisia	2
TT - Trinidad e Tobago	2
AM - Armenia	1
BB - Barbados	1
BH - Bahrain	1
CI - Costa d'Avorio	1
CR - Costa Rica	1
DK - Danimarca	1
EG - Egitto	1
ET - Etiopia	1
GT - Guatemala	1
HU - Ungheria	1
JM - Giamaica	1
LY - Libia	1
MD - Moldavia	1
MY - Malesia	1
NG - Nigeria	1
PT - Portogallo	1
PY - Paraguay	1
QA - Qatar	1
SN - Senegal	1
TL - Timor Orientale	1
UY - Uruguay	1
Totale	6.226

Salva come PNG Salva come JPEG

Città	#
Singapore	897
Hong Kong	537
Dallas	289
Chicago	259
Boardman	236
London	185
Ashburn	163
Beijing	156
The Dalles	112
Los Angeles	66
Santa Clara	64
São Paulo	46
Mexico City	43
New York	38
Munich	28
Assago	26
Brooklyn	25
Nuremberg	25
Orem	23
Johannesburg	21
Stockholm	20
Tokyo	20
Denver	19
Ho Chi Minh City	19
Milan	18
San Francisco	18
Warsaw	18
Atlanta	17
Poplar	16
Salt Lake City	16
Montreal	15
Ankara	14
Frankfurt am Main	14
Turku	14
Boston	13
Chennai	13
Dublin	13
Hanoi	13
Houston	12
Manchester	12
Belo Horizonte	11
Phoenix	11
Rio de Janeiro	11
Flanders	9
Toronto	9
Vergiate	9
Chandler	8
Düsseldorf	8
Helsinki	8
Moscow	8
Rome	8
Seattle	8
Tashkent	8
Vienna	8
Amsterdam	7
Buffalo	7
Porto Alegre	7
Baghdad	6
Cavaria con Premezzo	6
Charlotte	6
Contagem	6
Fairfield	6
Indianapolis	6
Nairobi	6
Piracicaba	6
Romola	6
Secaucus	6
São José dos Campos	6
Brasília	5
Campinas	5
Campo Grande	5
Erbil	5
Guidonia Montecelio	5
Jacksonville	5
Ottawa	5
Salvador	5
Sterling	5
Varese	5
Detroit	4
Fort Worth	4
Fortaleza	4
Goiânia	4
Haiphong	4
Joinville	4
Juiz de Fora	4
Kansas City	4
Miami	4
New Delhi	4
Querétaro	4
Riyadh	4
Anápolis	3
Brussels	3
Caruaru	3
Concord	3
Curitiba	3
Des Moines	3
Dhaka	3
Durban	3
Guarulhos	3
Guayaquil	3
Totale	3.892

Salva come PNG Salva come JPEG

Nome	#
AISF position paper on HCV in immunocompromised patients	139
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	51
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	48
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	46
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	46
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	45
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	45
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	44
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	44
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	43
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	43
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	43
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	42
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	42
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	41
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	40
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	39
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	39
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	38
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	38
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	38
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	38
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	38
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	38
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	38
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	37
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	36
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	36
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	36
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	35
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	35
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	35
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	35
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	34
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	34
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	34
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	34
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	33
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	33
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	32
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	32
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	32
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	32
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells	32
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	32
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	32
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance	32
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	32
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	31
Longitudinal Assessment of CLL Patients Under Ibrutinib Treatment Reveals Maintained Capacity to Respond to Microenvironmental Stimuli through the Toll-like Receptors	31
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	31
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	31
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	31
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results	31
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	31
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	31
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	31
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	31
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells	30
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	30
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	30
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	30
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism	30
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	30
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	30
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	30
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	29
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	29
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	29
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)	29
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	29
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL	29
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	29
OXIDATIVE STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA	29
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study	29
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance	29
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	29
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	29
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells	29
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	29
Effective anti-tumor immunomodulatory properties of zoledronic acid in Balb/c mice transgenic for the her-2/Neu oncogene	29
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	28
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS	28
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma	28
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	28
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	28
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target	28
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia	28
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	28
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	28
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS	28
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells	28
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	28
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	28
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	28
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	27
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	27
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE	27
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	27
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	27
Totale	3.433

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	42.892
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	42.892

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	15	0	0	0	0	0	2	0	4	2	2	1	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	2.943	411	465	436	846	458	327	0	0	0	0	0	0
Totale													6.467